Delfi Diagnostics: Thomas Russo

Delfi Diagnostics said that Thomas Russo has been appointed as CFO as the company expands into the blood-based liquid biopsy market with its FirstLook Lung cancer detection test. Russo had most recently worked as the CFO of pharmaceutical firm Icosavax, where he helped to guide the company through a growth period from its initial public offering through its acquisition by AstraZeneca. He also was the CFO of Assembly Biosciences, worked in senior finance and commercial operations roles at Gilead Sciences, and was an equity research senior analyst for biotechnology at Robert W. Baird & Co.